Open AccessBone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study
Author(s) -
Bart Morlion,
César Margarit,
Imane Wild,
Ravi Karra,
Hiltrud Liedgens,
Melanie Sohns,
Gabriele Finco
Publication year - 2021
Publication title -
pain management
Language(s) - English
Resource type - Journals
eISSN - 1758-1877
pISSN - 1758-1869
DOI - 10.2217/pmt-2020-0065
Subject(s) - tapentadol , oxycodone , medicine , exploratory analysis , osteoarthritis , retrospective cohort study , anesthesia , physical therapy , opioid , surgery , alternative medicine , data science , receptor , pathology , computer science
Aim: To explore fracture outcomes with tapentadol or oxycodone, two opioids with differing mechanisms of action. Materials & methods: Retrospective cohort pilot study, using MarketScan ® Commercial and Medicare Supplemental claims databases, on patients with postoperative pain, back pain, or osteoarthritis and ≥1 claim for tapentadol (n = 16,457), oxycodone (n = 1,356,920), or both (n = 15,893) between June 2009 and December 2015. Results: During 266,826 and 9,007,889 days of tapentadol and oxycodone treatment, patients evidenced 1080 and 72,275 fractures, respectively. Fracture rates per treatment-year were 1.512 for tapentadol and 3.013 for oxycodone. Conclusion: Examination of administrative claims has inherent limitations, but this exploratory analysis indicates a lower fracture rate with tapentadol than oxycodone in the analyzed dataset, which needs confirmation by further clinical trials.